A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

被引：0
|
作者：
Yang, Yan
Avvaru, Naga Suhasini
Jiang, Zaoli
Liu, Nina
Rosconi, Michael
Zhang, Bojie
Li, Yinyin
Ullman, Erica
Lin, John Chia-Yang
Shen, Yang
Daly, Christopher
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B129
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of FGFR3 Juxtamembrane Domain on FGFR3 Dimerization
    Sarabipour, Sarvenaz
    Li, Edwin
    Hristova, Kalina
    BIOPHYSICAL JOURNAL, 2011, 100 (03) : 546 - 546
  • [2] A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
    Yang, Yan
    Suhasini, Avvaru N.
    Jiang, Zaoli
    Liu, Nina
    Rosconi, Michael
    Zhang, Bojie
    Li, Yinyin
    Dudgeon, Drew
    Seong, Changhyun
    Kim, Steven
    Rafique, Ashique
    Huang, Tammy
    Bhosle, Sangram
    Krueger, Pamela
    Ullman, Erica
    Olson, William
    Lin, John C.
    Shen, Yang
    Daly, Christopher
    CANCER RESEARCH, 2024, 84 (13) : 2169 - 2180
  • [3] Dimerization of FGFR3 in Living Cells
    Singh, Deo R.
    King, Chris
    Placone, Jesse
    Cao, Qingqing
    Ghosh, Praveen
    Hristova, Kalina
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 480A - 480A
  • [4] A kinase deleated FGFR3 inhibits FGFR3 activity in-vivo
    Zebavi-Feferman, T
    Madar-Shapiro, L
    Chumakov, I
    Rom, E
    Yayon, A
    MOLECULAR BIOLOGY OF THE CELL, 1998, 9 : 235A - 235A
  • [5] Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Andrew J. Weickhardt
    David K. Lau
    Margeaux Hodgson-Garms
    Austen Lavis
    Laura J. Jenkins
    Natalia Vukelic
    Paul Ioannidis
    Ian Y. Luk
    John M. Mariadason
    BMC Cancer, 22
  • [6] Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Weickhardt, Andrew J.
    Lau, David K.
    Hodgson-Garms, Margeaux
    Lavis, Austen
    Jenkins, Laura J.
    Vukelic, Natalia
    Ioannidis, Paul
    Luk, Ian Y.
    Mariadason, John M.
    BMC CANCER, 2022, 22 (01)
  • [7] Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGFR3 translocated tumor models
    Minh Nguyen
    Lin, Kevin K.
    Burbridge, Mike F.
    Simmons, Andrew D.
    Harding, Thomas C.
    CANCER RESEARCH, 2015, 75
  • [8] Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
    Wang, Zechen
    Muthusamy, Viswanathan
    Petrylak, Daniel P.
    Anderson, Karen S.
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [9] Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
    Zechen Wang
    Viswanathan Muthusamy
    Daniel P. Petrylak
    Karen S. Anderson
    npj Precision Oncology, 7
  • [10] Secreted FGFR3, but not FGFR1, inhibits lens fiber differentiation
    Govindarajan, V
    Overbeek, PA
    DEVELOPMENT, 2001, 128 (09): : 1617 - 1627
12345